Evidence map›Paper›PMID 39618959›Full record

ArticleJGH open : an open access journal of gastroenterology and hepatology2024

Evaluating Disparities in COVID-19 Clinical Outcomes Among Patients With Cirrhosis in North America and Europe-An International Registry Study.

Umar Hayat, Andrew M Moon, Manesh K Gangwani, Fariha Hasan, Thomas Marjot, A Sidney Barritt, Wasique Mirza, Duane Deivert, Muhammad Aziz, Dushyant Singh Dahiya and 3 more

Abstract read
In one paragraph

Article in JGH open : an open access journal of gastroenterology and hepatology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Umar HayatDepartment of Internal Medicine Geisinger Wyoming Valley Medical Center Wilkes-Barre Pennsylvania USA.
Andrew M MoonDivision of Gastroenterology and Hepatology University of North Carolina at Chapel Hill Chapel Hill North Carolina USA.
Manesh K GangwaniDepartment of Gastroenterology and Hepatology University of Arkansas for Medical Sciences Little Rock Arkansas USA.
Fariha HasanDepartment of Internal Medicine Cooper University Hospital Camden New Jersey USA.
Thomas MarjotOxford Centre for Diabetes, Endocrinology and Metabolism, Radcliffe Department of Medicine University of Oxford Oxford UK.
A Sidney BarrittDivision of Gastroenterology and Hepatology University of North Carolina at Chapel Hill Chapel Hill North Carolina USA.
Wasique MirzaDepartment of Internal Medicine Geisinger Wyoming Valley Medical Center Wilkes-Barre Pennsylvania USA.
Duane DeivertDepartment of Internal Medicine Geisinger Wyoming Valley Medical Center Wilkes-Barre Pennsylvania USA.
Muhammad AzizDepartment of Gastroenterology and Hepatology Mercy Hospital Toledo Ohio USA.ORCID https://orcid.org/0000-0001-5620-8597
Dushyant Singh DahiyaDepartment of Gastroenterology and Hepatology University of Kansas Medical Center Kansas Missouri USA.ORCID https://orcid.org/0000-0002-8544-9039
Hassam AliDepartment of Gastroenterology and Hepatology East Carolina University Greenville North Carolina USA.ORCID https://orcid.org/0000-0001-5546-9197
Sumant InamdarDivision of Gastroenterology and Hepatology University of Arkansas Little Rock Arkansas USA.
Mauricio Garcia-Saenz-de-SiciliaDivision of Gastroenterology and Hepatology University of Arkansas Little Rock Arkansas USA.

Funding

UNC-CH CENTER FOR ENVIRONMENTAL HEALTH &SUSCEPTIBILITYP30ES010126 · NIEHS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Hazel B Nichols · 2001 to 2026
$36.3M
NIEHS NIH HHS P30 ES010126
6 · The paper itself

Abstract

Background: Patients with decompensated cirrhosis have a higher risk of hospitalization, ICU admission, and death from COVID-19. The impact of demographics on these outcomes remains uncertain. Methods: The SECURE-Liver and COVID-Hep databases were utilized to evaluate disparities in COVID-19 outcomes. Patients were stratified by North American and European cohorts. Bivariate and multivariable logistic regression was performed. Results: A total of 718 cirrhosis patients with COVID-19 were evaluated. In the North American cohort, Black patients had more comorbidities (CI: 1.86 vs. 1.83, Conclusion: Black patients in North America had higher hospitalization, ICU admission, and death rates. In the European subgroup, White patients had higher death rates than non-White patients. These disparities became statistically insignificant after adjusting for confounders, suggesting that non-liver-related comorbidities might increase the risk of adverse outcomes.

Indexed as

COVID‐19COVID‐Hepdecompensated cirrhosisracial disparitiesSECURE‐Liver

Identifiers

PMID39618959
PMCPMC11605158

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.